Tranzyme is developing TZP-101 as a first-in-class gastroprokinetic agent for the treatment of severe gastroparesis and post-operative ileus (POI).
The data from its pilot phase IIa study was presented at the American Diabetes Association’s 67th Scientific Sessions in Chicago.
Using scintigraphy and a standardized meal, this double blind, randomized, four-way crossover study assessed the efficacy of three different dose levels of TZP-101 on gastric emptying in patients with type 1 diabetes and severe gastroparesis.
According to the company, TZP-101 significantly accelerated gastric emptying at all doses tested, whereas placebo had no effect. Tranzyme says these results suggest that TZP-101 is a promising agent for the management of gastroparesis and that further investigation is warranted.
Gastroparesis results from dysfunction of the nerves of the stomach, leading to postprandial fullness, bloating, early satiety, nausea and vomiting. It is a common disorder among diabetics.